Friday, 18 Jan 2019

You are here

Cardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA

Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides. A single center cross -sectional observational study was designed to conduct deeper analysis of Cardiovascular Risk Factors (CVRF) in patients with PsA, PSO without arthritis and SpA without PSO (THU 0297). Authors aimed at identifying association between CVRF and presence of either arthritis or skin disease. 

In this study of 300 patients with PSA, PSO and SpA, 29.7% reported Hypertension (HTN), 11.7% Type 2 Diabetes Melitus(T2DM) and 29% Dyslipidemia (DL). In comparison with general population entire study group comprised 100 patients with SpA without PSO (33.3%), 100 patients with PsA (33.3%) and PSO without articular disease (13%) exhibited higher prevalence of HTN and DL (p <0.005). Inside the study group though, where was no significant difference in prevalence of CVEF between all three studied diagnoses ( Fig below).

HTN was significantly associated with AINEs intake (OR 1.79; p<0.005) and disease duration (OR 1.02). No association with gender or age was found in this study.  neither PSA/SpA nor PSO were associated with development of T2DM or dyslipidemia. 

Study concluded that although prevalence of CVRF was higher in the study group comparing to general population, no significant difference was found in regards to skin vs articular disease. authors hint at association between NSAIDs use and HTN which would require further studies to specify.

image2.jpeg

 

image3.jpeg

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diet and Weight Loss Improves Psoriatic Arthritis

Short-term intervention with the very low energy diet (VLED) in psoriatic arthritis (PsA) with obesity (body mass index BMI ≥ 33 kg/m2) showed that weight loss was associated with significant positive benefits on weight and disease activity in joints, entheses and skin. 

H2H: Ixekizumab vs. Adalimumab in Psoriatic Arthritis

Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.

SPIRIT-H2H study was designed as a large head-to-head (H2H) superiority study to assess the efficacy and safety of ixekizumab versus adalimumab active psoriatic arthritis (PsA) patients who are biologic naive.

Psoriatic Arthritis Does Not Add to Pregnancy Problems

When psoriatic arthritis (PsA) patients become pregnant, they do not have more infertility or adverse pregnancy outcomes compared to healthy controls.

This study is relevant as the average onset age of PsA ranges between the 4th-6th decades of life and therefore includes a period of child-bearing potential.

IL-23 Outduels IL-17 Inhibition in Psoriasis

Johnson & Johnson has announced the preliminary results of its phase 3 ECLIPSE study; a head-to-head trial wherein guselkumab (Tremfya; an IL-23 inhibitor) was compared to secukinumab (Cosentyx; an IL-17 inhibitor) in adults with moderate to severe plaque psoriasis.

New ACR/NPF Guidelines for Management of Psoriatic Arthritis

The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA) that provides evidence-based pharmacologic and non-pharmacologic recommendations and includes recommendations on other management issues including vaccinations, psoriatic spondylitis, enthesitis, and treatment in the presence of inflammatory bowel disease, diabetes, or serious infections.